Celsion

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time

Celsion Corporation Reports 2021 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines.

Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

A 1-for-15 reverse split of Celsion Corporation (NASDAQ: CLSN) stock has gone into effect. These are the details.

Celsion (CLSN) Stock: 1-For-15 Reverse Split Goes Into Effect

Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024

Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses

LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of its outstanding Common Shares on the basis of one (1) new Common Share for every fifteen (15) currently outstanding Common Shares.

Celsion Corporation Announces Stock Consolidation

Preclinical results d emonstrate safe and efficient immune response with v accine development showing promise of neutralizing activity for a range of variants

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced the closing of its previously announced registered direct offering with certain institutional investors to purchase 50,000 shares of Series A convertible redeemable preferred stock and 50,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B preferred stock had a purchase price of $285, representing an original issue discount of 5% of the $300 stated value of each share, resulting in net proceeds of approximately $28.5 million, before deducting placement agent's fees and other estimated offering expenses.

Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock

Celsion Corporation 's GEN-1 IL-12 Program in Ad vanced Ovarian Cancer to be Featured in Poster Presentation

Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit

Celsion Corporation (CLSN) CEO Michael Tardugno on Q3 2021 Results - Earnings Call Transcript

Balance Sheet Supports Focus o n Immuno-Oncology and Next-Generation Vaccine Initiative

Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, November 15, 2021 to discuss financial results for third quarter ended September 30, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines.

Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021

Application A pproval Will Further Extend Current Operating Runway to Over Three Years

Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses

Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions

Celsion Corporation's GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit

Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual P resentation Monday, October 18 at 7:30 a.m. Eastern Time

Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

The stock price of Celsion Corporation (NASDAQ: CLSN) increased from $0.88 on Thursday to about $0.95-$1 today. This is why it happened.

CLSN Stock: Why It Increased This Week

Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual P resentation on Celsion's O ngoing W ork with DNA-based V accines

Celsion Corporation Announces Oral Presentation at International Vaccines Congress

Investigator-Sponsored Research with ThermoDox ® Continues in Multiple Indications

Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews

LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development program, and the hiring of a veteran clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer. These changes all are effective immediately and are as follows:

Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

E xpands GEN-1 P rogram C ollaboration to Add C linical and C ommercial B atches of I nvestigational V accine

Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion's DNA-based Vaccine

Advaxis

Tellurian

Why investors are watching these 3 penny stocks right now The post Hot Penny Stocks to Add to Your September Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Add to Your September Watchlist

Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.

Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies

Dare Bioscience

Meta Materials

Are these penny stocks on your watchlist in August 2021? The post Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?

Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?

Celsion Corporation (CLSN) CEO Michael Tardugno on Q2 2021 Results - Earnings Call Transcript

Camber Energy

NanoVibronix

Electrameccanica

What you need to know about these 4 penny stocks this week? The post Penny Stocks to Buy This Week?

Penny Stocks to Buy This Week? 4 You Need to Know About

LAWRENCEVILLE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. EDT on Thursday, August 12, 2021 to discuss financial results for the second quarter ended June 30, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines.

News for Celsion Stock (CLSN)